Skip to content
Terminus Peptides
  • Research use only — not for human or veterinary use
  • 55 compound profiles, every source cited
  • 62 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Combination

Klow combination

Also known as KLOW blend

In vitro — evidence level 1 of 4: In-vitro evidenceExperimental — UK regulatory status: Experimental — not authorised for human use in the UK

Overview

A four-peptide mixture. Literature searches under this name return no scientific results at all.

Category
Combination
Highest evidence level identified
In-vitro evidence
Last scientifically reviewed
20 August 2026
Last regulatory review
20 August 2026

Mechanism under investigation

Klow is the Glow mixture with a fourth peptide added: KPV, a tripeptide corresponding to the last three residues of alpha-melanocyte-stimulating hormone, studied preclinically for anti-inflammatory activity in gastrointestinal models. Adding a fourth pharmacologically unrelated agent to an already untested three-way mixture multiplies the number of possible interactions rather than adding a fourth independent benefit. No framework exists for predicting the behaviour of this quartet from its parts.

Research areas

  • Combination pharmacology

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

None.

Animal evidence

Studies in living non-human animals.

None.

Human observational evidence

Studies observing people without assigning an intervention.

None.

Clinical-trial evidence

Studies assigning an intervention to human participants.

None. There are no registered trials of the combination, and KPV returns no registered trials even as a single agent. A literature search under this blend name returns hundreds of records, every one of which is an unrelated Norwegian surname. There is no scientific literature on this mixture whatsoever.

Study limitations

  • The evidence level shown is the floor of the framework and overstates the position. The combination has not been tested at any level. There is no evidence for this mixture at all.
  • There is no standardised composition, and the problem is worse than for the three-peptide version: with four components the range of possible ratios is larger and supplier formulations diverge further.
  • KPV has the thinnest evidence base of the four constituents — cell and animal work only, concentrated in inflammatory bowel disease models, with no human efficacy trials and no registered trials of any kind.
  • The same sample-quality findings apply, compounded by a four-component mixture offering four opportunities for substitution, under-fill or contamination, with no practical way for a purchaser to verify any of them.

UK regulatory context

Experimental — not authorised for human use in the UK

A compound appearing in research literature that holds no UK authorisation for human use in any indication.

Source: The Human Medicines Regulations 2012, regulation 46 — prohibition on sale or supply of an unauthorised medicinal product (opens legislation.gov.uk in a new tab) (legislation.gov.uk)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

No safety data exist for this combination. The melanocortin pathway that KPV engages is distinct from the targets of the other three, so no read-across is possible even in principle. As with the three-peptide version, the realistic hazard profile is dominated by unregulated product quality rather than by characterised pharmacology, and the four-component format increases that exposure rather than reducing it.

References